The Effect of Dialysate Bicarbonate Concentration or Oral Bicarbonate Supplementation on Outcomes in Patients on Maintenance Dialysis: A Systematic Review and Meta-Analysis.

IF 1.5 Q3 UROLOGY & NEPHROLOGY
Canadian Journal of Kidney Health and Disease Pub Date : 2025-07-31 eCollection Date: 2025-01-01 DOI:10.1177/20543581251356182
Ashlee M Azizudin, Samuel A Silver, Amit X Garg, Zoe K Friedman, Andrea C Cowan, Catherine M Clase, Amber O Molnar
{"title":"The Effect of Dialysate Bicarbonate Concentration or Oral Bicarbonate Supplementation on Outcomes in Patients on Maintenance Dialysis: A Systematic Review and Meta-Analysis.","authors":"Ashlee M Azizudin, Samuel A Silver, Amit X Garg, Zoe K Friedman, Andrea C Cowan, Catherine M Clase, Amber O Molnar","doi":"10.1177/20543581251356182","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic acidosis is a common complication of kidney failure that is treated with bicarbonate supplementation. The addition of bicarbonate to the dialysis solution and oral bicarbonate supplementation are used to treat metabolic acidosis in patients receiving dialysis, but the treatment approach that is best for patient health remains unknown.</p><p><strong>Objective: </strong>The purpose of this study was to determine whether the concentration of dialysate bicarbonate or the use of oral bicarbonate supplementation alters the risk of mortality, hospitalizations, cardiovascular and nutritional outcomes, and laboratory measurements in patients treated with maintenance dialysis.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Setting: </strong>Any country of origin.</p><p><strong>Patients: </strong>Adult patients (≥18 years) receiving maintenance dialysis.</p><p><strong>Measurements: </strong>Extracted data included demographic characteristics and outcomes such as mortality, hospitalizations, cardiovascular events, surrogate markers of nutrition, and pre-dialysis and post-dialysis levels of serum bicarbonate, pH, calcium, potassium, and parathyroid hormone.</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, CENTRAL, and Google Scholar through October 7, 2024 for studies examining dialysate bicarbonate concentration and/or oral bicarbonate supplementation in adults undergoing maintenance dialysis. Meta-analysis was performed for pre-dialysis serum bicarbonate and for pre-dialysis and post-dialysis calcium and potassium.</p><p><strong>Results: </strong>We identified 37 studies (n = 24,782 patients) with patients treated with hemodialysis (13 randomized trials, 10 non-randomized interventional studies, 14 observational studies) and 4 studies (n = 347 patients) with patients receiving peritoneal dialysis (3 randomized trials, 1 non-randomized interventional study). No randomized trials reported mortality or hospitalizations in hemodialysis patients. Studies reporting cardiovascular outcomes (n = 20) were small with inconsistent results. Most studies reporting nutritional outcomes (n = 21) reported no significant differences with dialysate bicarbonate concentration or oral bicarbonate supplementation but were small in sample size (largest study n = 200). Meta-analysis of parallel-group randomized trials comparing dialysate bicarbonate >35 mmol/L with ≤35 mmol/L found a mean difference of 3.5 mmol/L (95% confidence interval [CI] -0.6 to 7.7) in pre-dialysis serum bicarbonate.</p><p><strong>Limitations: </strong>Non-English and gray literature were excluded. Most studies were small or observational in nature, and heterogeneity further limited the ability to perform meta-analysis of outcomes such as mortality, hospitalizations, and cardiovascular outcomes.</p><p><strong>Conclusions: </strong>The evidence for the effect of higher vs lower dialysate bicarbonate concentration and oral bicarbonate supplementation on clinical outcomes in dialysis patients is very uncertain. There is a need for large, high-quality randomized controlled trials in this area.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"12 ","pages":"20543581251356182"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Kidney Health and Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20543581251356182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Metabolic acidosis is a common complication of kidney failure that is treated with bicarbonate supplementation. The addition of bicarbonate to the dialysis solution and oral bicarbonate supplementation are used to treat metabolic acidosis in patients receiving dialysis, but the treatment approach that is best for patient health remains unknown.

Objective: The purpose of this study was to determine whether the concentration of dialysate bicarbonate or the use of oral bicarbonate supplementation alters the risk of mortality, hospitalizations, cardiovascular and nutritional outcomes, and laboratory measurements in patients treated with maintenance dialysis.

Design: Systematic review and meta-analysis.

Setting: Any country of origin.

Patients: Adult patients (≥18 years) receiving maintenance dialysis.

Measurements: Extracted data included demographic characteristics and outcomes such as mortality, hospitalizations, cardiovascular events, surrogate markers of nutrition, and pre-dialysis and post-dialysis levels of serum bicarbonate, pH, calcium, potassium, and parathyroid hormone.

Methods: We searched MEDLINE, Embase, CENTRAL, and Google Scholar through October 7, 2024 for studies examining dialysate bicarbonate concentration and/or oral bicarbonate supplementation in adults undergoing maintenance dialysis. Meta-analysis was performed for pre-dialysis serum bicarbonate and for pre-dialysis and post-dialysis calcium and potassium.

Results: We identified 37 studies (n = 24,782 patients) with patients treated with hemodialysis (13 randomized trials, 10 non-randomized interventional studies, 14 observational studies) and 4 studies (n = 347 patients) with patients receiving peritoneal dialysis (3 randomized trials, 1 non-randomized interventional study). No randomized trials reported mortality or hospitalizations in hemodialysis patients. Studies reporting cardiovascular outcomes (n = 20) were small with inconsistent results. Most studies reporting nutritional outcomes (n = 21) reported no significant differences with dialysate bicarbonate concentration or oral bicarbonate supplementation but were small in sample size (largest study n = 200). Meta-analysis of parallel-group randomized trials comparing dialysate bicarbonate >35 mmol/L with ≤35 mmol/L found a mean difference of 3.5 mmol/L (95% confidence interval [CI] -0.6 to 7.7) in pre-dialysis serum bicarbonate.

Limitations: Non-English and gray literature were excluded. Most studies were small or observational in nature, and heterogeneity further limited the ability to perform meta-analysis of outcomes such as mortality, hospitalizations, and cardiovascular outcomes.

Conclusions: The evidence for the effect of higher vs lower dialysate bicarbonate concentration and oral bicarbonate supplementation on clinical outcomes in dialysis patients is very uncertain. There is a need for large, high-quality randomized controlled trials in this area.

Abstract Image

Abstract Image

Abstract Image

碳酸氢盐透析液浓度或口服补充碳酸氢盐对维护性透析患者结局的影响:一项系统回顾和荟萃分析。
背景:代谢性酸中毒是补充碳酸氢盐治疗肾衰竭的常见并发症。在透析液中添加碳酸氢盐和口服碳酸氢盐补充剂用于治疗接受透析的患者的代谢性酸中毒,但最适合患者健康的治疗方法仍不清楚。目的:本研究的目的是确定碳酸氢盐透析液的浓度或口服碳酸氢盐补充剂的使用是否会改变维持透析患者的死亡率、住院率、心血管和营养结局以及实验室测量的风险。设计:系统回顾和荟萃分析。设定:任何原产国。患者:接受维持性透析的成人患者(≥18岁)。测量:提取的数据包括人口统计学特征和结果,如死亡率、住院率、心血管事件、营养替代标志物、透析前和透析后血清碳酸氢盐、pH、钙、钾和甲状旁腺激素水平。方法:我们检索了MEDLINE、Embase、CENTRAL和谷歌Scholar,检索了2024年10月7日之前有关透析液碳酸氢盐浓度和/或口服碳酸氢盐补充在维持透析成人中的研究。对透析前血清碳酸氢盐、透析前和透析后钙和钾进行meta分析。结果:我们纳入了37项研究(n = 24,782例患者),涉及接受血液透析治疗的患者(13项随机试验,10项非随机介入性研究,14项观察性研究)和4项研究(n = 347例患者),涉及接受腹膜透析的患者(3项随机试验,1项非随机介入性研究)。没有随机试验报告血液透析患者的死亡率或住院率。报告心血管结果的研究(n = 20)较少,结果不一致。大多数报告营养结果的研究(n = 21)报告碳酸氢盐透析液浓度或口服碳酸氢盐补充没有显著差异,但样本量较小(最大的研究n = 200)。比较透析液碳酸氢盐浓度为35 mmol/L和≤35 mmol/L的平行组随机试验的荟萃分析发现,透析前血清碳酸氢盐的平均差异为3.5 mmol/L(95%可信区间[CI] -0.6至7.7)。局限性:非英语文献和灰色文献被排除在外。大多数研究都是小规模或观察性的,异质性进一步限制了对死亡率、住院率和心血管结局等结果进行荟萃分析的能力。结论:高/低透析液碳酸氢盐浓度和口服碳酸氢盐补充对透析患者临床结局的影响证据非常不确定。在这一领域需要进行大规模、高质量的随机对照试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
5.90%
发文量
84
审稿时长
12 weeks
期刊介绍: Canadian Journal of Kidney Health and Disease, the official journal of the Canadian Society of Nephrology, is an open access, peer-reviewed online journal that encourages high quality submissions focused on clinical, translational and health services delivery research in the field of chronic kidney disease, dialysis, kidney transplantation and organ donation. Our mandate is to promote and advocate for kidney health as it impacts national and international communities. Basic science, translational studies and clinical studies will be peer reviewed and processed by an Editorial Board comprised of geographically diverse Canadian and international nephrologists, internists and allied health professionals; this Editorial Board is mandated to ensure highest quality publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信